A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.
Latest Information Update: 18 Aug 2022
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Sinovac Biotech
- 10 Aug 2022 Status changed from active, no longer recruiting to completed.
- 26 Jul 2021 Planned primary completion date changed from 15 Jul 2021 to 1 Aug 2021.
- 03 Jun 2021 Status changed from recruiting to active, no longer recruiting.